294 related articles for article (PubMed ID: 32193356)
21. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
Xia CQ; Liu N; Yang D; Miwa G; Gan LS
Drug Metab Dispos; 2005 May; 33(5):637-43. PubMed ID: 15716365
[TBL] [Abstract][Full Text] [Related]
22. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
23. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
25. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
[TBL] [Abstract][Full Text] [Related]
26. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
27. Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).
Haslam IS; Wright JA; O'Reilly DA; Sherlock DJ; Coleman T; Simmons NL
Drug Metab Dispos; 2011 Dec; 39(12):2321-8. PubMed ID: 21930826
[TBL] [Abstract][Full Text] [Related]
28. Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Sawangrat K; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2018 Nov; 107(11):2946-2956. PubMed ID: 30053556
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
30. Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2.
Harwood MD; Neuhoff S; Rostami-Hodjegan A; Warhurst G
J Pharm Sci; 2016 Apr; 105(4):1370-5. PubMed ID: 26952881
[TBL] [Abstract][Full Text] [Related]
31. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
Zhang W; Li J; Allen SM; Weiskircher EA; Huang Y; George RA; Fong RG; Owen A; Hidalgo IJ
Drug Metab Dispos; 2009 Apr; 37(4):737-44. PubMed ID: 19131524
[TBL] [Abstract][Full Text] [Related]
32. Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs.
Kono Y; Kawahara I; Shinozaki K; Nomura I; Marutani H; Yamamoto A; Fujita T
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33804018
[TBL] [Abstract][Full Text] [Related]
33. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
34. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
36. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
37. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
38. Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines.
Yano K; Okabe C; Fujii K; Kato Y; Ogihara T
J Pharm Pharmacol; 2020 Apr; 72(4):575-582. PubMed ID: 31975441
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
40. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
